BridgeBio Pharma Inc. announced a proposed private offering of $550 million aggregate principal amount of convertible senior notes due 2033. The company may also grant initial purchasers an option to buy up to an additional $82.5 million of these notes. The proceeds are intended to be used to repurchase, settle future conversion obligations in respect of, or repay at maturity a portion of the company’s 2.50% convertible senior notes due 2027, as well as for general corporate purposes such as working capital, capital expenditures, and debt repayment. The offering is aimed at strengthening the balance sheet, lowering interest expense, reducing dilution, and extending debt maturity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9626001-en) on January 14, 2026, and is solely responsible for the information contained therein.